| abstract |
The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes. |